

Validity of Prognostic Scoring Systems in Egyptian Patient with Chronic Myeloid Leukemia

Thesis

*Submitted for Fulfillment of Master Degree
In Clinical Haematology*

BY

Douaa Ramadan Attia Abdelkarim

(M.B.B.CH.)

Faculty of Medicine –Cairo University

Supervised By

Prof. DR. Mohamed Osman Azzazi

Professor of Internal Medicine,

Clinical Haematology & Oncology

Faculty of Medicine – Ain Shams University

Prof. DR. Hany Mohamed Ab-Allah

Professor of Internal Medicine,

Clinical Haematology & Oncology

Faculty of Medicine – Ain Shams University

DR. Emad Abd El-Mohsen Abd El-hady

Assistant professor of Clinical Haematology & Oncology

Faculty of Medicine – Ain Shams University

Faculty of Medicine

Ain Shams University

2016

صلاحيّة الأنظمة التنبؤيّة للتطبيّق علي مرضي

سرطان الدم النقيوي المزمن في مصر

توطئة للحصول على درجة الماجستير في أمراض الدم

مقدمة من

الطبيبة/ دعاء رمضان عطية عبد الكريم

بكالوريوس الطب والجراحة العامة

كلية الطب - جامعة عين شمس

تحت إشراف

أ. د/ محمد عثمان عزازي

أستاذ الباطنة وأمراض الدم الاكلينيكية والأورام

كلية الطب - جامعة عين شمس

أ. د/ هاني محمد عبد الله حجاب

أستاذ الباطنة وأمراض الدم الاكلينيكية والأورام

كلية الطب - جامعة عين شمس

الدكتور/ عماد عبد المحسن عبد الهادي

أستاذ مساعد أمراض الباطنة وأمراض الدم الاكلينيكية والأورام

كلية الطب - جامعة عين شمس

كلية الطب

جامعة عين شمس

٢٠١٦

بِسْمِ اللَّهِ الرَّحْمَنِ الرَّحِيمِ

قالوا

سبحانك لا علم لنا
إلا ما علمتنا إنك أنت
العليم العظيم

صدق الله العظيم

سورة البقرة الآية: ٣٢



Acknowledgements

First of **All**, I thank Allah for allowing me to finish this work.

In a few grateful words, I would like to express my deepest gratitude and appreciation to Professor **Dr. Mohamed Osman Azzazi.** Professor of Internal Medicine, Clinical Haematology & Oncology Faculty of Medicine – Ain Shams University, for his unlimited help, kind encouragement and generous support throughout this whole work. It was a great honor for me to work under his guidance and supervision.

I also would like to express my gratitude to **Dr. Hany Mohamed Abd-Allah.** Assistant Professor of Internal Medicine, Clinical Haematology & Oncology, Faculty of Medicine – Ain Shams University for her great help, sincere guidance and valuable advice throughout this work.

I also would like to express my gratitude to **Dr. Emad Abd El-Mohsen Abd El-hady,** Assistant Lecturer of Clinical Haematology & Oncology, Faculty of Medicine – Ain Shams University for her great help, sincere guidance and valuable advice throughout this work.

I am deeply indebted to my family for their generous support and continuous encouragement.

List of Contents

Title	Page
• List of Table.....	I
• List of Figure	V
• List of Abbreviation.....	VIII
• Introduction.	1
• Aim of the Study	4
• Review of Literature.....	
• Chapter (1): Chronic myeloid leukemia	5
• Chapter (2): ABL1 fusion genes.....	76
• Chapter (3): Scoring Systems	89
• Subjects And Methods.....	115
• Results	126
• Discussion	156
• Summary.....	169
• Conclusion	170
• Recommendations.....	171
• References.....	172
• Master Sheet.....	225
• Arabic Summary.....	-

List of Tables

Review of Literature

Title	Page
Table 1: CML incidence of eight different population-based registries or surveys.....	8
Table 2: Criteria for accelerated phase according to IBMTR, and WHO	25
Table 3: Definitions of blastic crisis	27
Table 4: Frequency of adverse effects among patients receiving imatinib for chronic myeloid leukemia	35
Table 5: Results of dasatinib and nilotinib following imatinib failure due to resistance or intolerance.....	50
Table 6: Treatment Options Basedon BCR-ABL Kinase Domain Mutation Status.....	52
Table 7: The EBMT prognostic scoring system for patients with CMLtreated with HSCT.....	59
Table 8: Definitions of hematologic, cytogenetic, and molecular response in chronic myeloid leukemia.	61

✍ List of Tables

Table 9: Monitoring Intervals:(guidelines of ELN & NCCN).....	69
Table 10: Response assessment in CML	70
Table 11: Follow up therapy recommendations	71
Table 12: Calculation of Risk Score	74
Table 13: Comparison of the Sokal, Hasford, and EUTOS scores	102
Table 14: EUTOS score validation studies.....	105
Table 15: AmpliMaster kit component.....	120

Results

Title	Page
Table 1: Characteristics of all CML patients	127
Table 2: Baseline laboratory data of all CML patients	128
Table 3: Baseline Sokal, Hasford, and EUTOS scores of CML patients at diagnosis	129
Table 4: Outcome measures at 3 months according to ELN criteria 2013	130
Table 5: Outcome measures to TKIs therapy at 6 months	131
Table 6: Relation between the Sokal score and response to treatment	136
Table 7: Relation between the Hasford score and response to treatment	138
Table 8: Relation between the EUTOS score and response to treatment	140
Table 9: Predictive Power of the 3 Scores for CHR / CCyR/ EMR at 6 months.....	142
Table 10: Prediction of OR and failure at 6 months according to ELN criteria using the 3 Scores.	145
Table 11: Receiver-operating characteristic (ROC) curve analysis for prediction of optimal response by	

List of Tables

ELN criteria at 6 months using the Sokal score,
Hasford score, or EUTOS score 147

Table 12: Receiver-operating characteristic (ROC) curve
analysis for prediction of failure by ELN criteria
at 6 months using the Sokal score, Hasford score,
or EUTOS score..... 149

Table 13: Relation between Sokal score and response at 6
months by ELN criteria 152

Table 14: Abbreviations, definitions, and response
categories in discussion 168

List of Figures

Title	Page
Figure 1: Annual incidence per 100,000 inhabitants in different age groups of CML patients (n=1039 diagnosed in 2002-2012.....	9
Figure 2: Age-standardised annual incidence (adjusted to WSP) of CML diagnosed in 1970–2010.....	10
Figure 3: Estimated prevalence of chronic myeloid leukemia in the USA by calendar year, from Huang et al.....	11
Figure 4: The Philadelphia chromosome: Reciprocal ranslocation between the long arms of chromosomes 9and 22 [t(9;22) (q34;qll) j.	16
Figure 5: Evolution of CML with prophases –a proposed hypothesis.	20
Figure 6: Survival with imatinib mesylate versus interferon.....	34
Figure 7: Summary of potential mechanisms of resistance to imatinib.....	48
Figure 8: European Leukemia Net definitions of failure or suboptimal response detected in patients in CML-CP treated with irnatinib.....	60

List of Figures

- Figure 9:** Schematic representation of the ABL1 gene and the break point sites of the seven types of fusion genes identified thus far black rectangles represent exons 78
- Figure 10:** Schematic representation of the ABL1 protein and the fusion proteins 82
- Figure 11:** Percentage of patients treated with imatinib mesylate (Glivec) or nilotinib (Tasigna). 127
- Figure 12:** Baseline Sokal, Hasford, and EUTOS scores in the study population..... 129
- Figure 13:** Outcome measures to TKIs therapy at 3 months..... 131
- Figure 14:** Outcome measures at 6 months.. 132
- Figure 15:** Response to treatment by ELN criteria at 6 months..... 132
- Figure 16:** Relation between the Sokal score and response to treatment at 6 months by ELN criteria 137
- Figure 17:** Relation between the Hasford score and response to treatment at 6 months by ELN criteria 139
- Figure 18:** Relation between the EUTOS score and response to treatment at 6 months by ELN criteria..... 141

Figure 19: Receiver-operating characteristic (ROC) curves based on the multivariable binary logistic regression models for prediction of optimal response by ELN criteria at 6 months using the Sokal score.....	148
Figure 20: Receiver-operating characteristic (ROC) curves based on the multivariable binary logistic regression models for prediction of failure by ELN criteria at 6 months using the Sokal score	150

List of Abbreviations

ABL	Abelson protonocogene
ACA	Additional chromosomal anomalies
AP	Accelerated phase
ATP	Adenosine triphosphate
BCR	Break point cluster region gene
BP	Blastic phase
CBL	Casitas B lineage c lymphoma protein
CCR	Complete cytogenetic response
CML	Chronic myeloid leukemia
CP	Chronic phase
Der	Derivative
EFS	Event-free survival
ELN	European leukemia net
EUTOS	European Treatment and Outcome Study
FDA	Food & drug administration
FFS	Failure free survival
FISH	Flouresceneinsitu hybridization
HLA	Human Leukocytic Antigen
HMRN	The British Haematological Malignancy Research Network
HS	Highly significant
i17	Isochromosome 17
IBMT	International Bone marrow Transplantation
IFN-α	Interferon-alpha
IM	Imatinib mesylate

List of Abbreviations

Inv	Inversion
IRIS	International ranomised study of interferone
JUN	Oncogene
Kb	Kilobase
KD	Kinase domain
KDa	Kilo Dalton
MDA	MD Anderson
MMR	Major: Molecular response
MYC	Oncogene
NCCN	National comprehensive cancer network
NS	No significant
NW	Northern
OS	Overall survival
PCR	Polymerase chain reaction
PFS	Progression-free survival
PGDFR	Platelet derived growth factor receptor
Ph	Philadelphia chromosome
RAF	Rapidly accelerated fibroblastoma
RAS	Rat sarcoma
RAS-MAPK	RAS mitogen activated protein oncogene
RB1	Retinoblastma protein
RBP	Receptor bound protein
SCT	Stem cell transplantation
SEER	Surveillance epidemiology end results
SPSS	Statistical program for social science
SRC	Protooncogene for sarcoma

List of Abbreviations

STAT	Signal transducers & activators of transcription
Sw	Swedish
TFS	Transformation-free survival
TK	Tyrosine kinase
TKI	Tyrosine kinase inhibitor
WHO	World Health Organization
WSP	World Standard Population